RxDoctor Payments Data

Nassim Nabavi, PA

Medical · Marietta, GANPI 1205297983

Payments from drug & device makers

$8,724in general payments, 2019–2025

Across 416 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$544
  • SK Life Science, Inc.$438
  • Biogen$398
  • Lundbeck LLC$381
  • MDD US Operations, LLC$311
  • plus $5K from 51 others

What the payments were for

  • Food & beverage$8,62999%
  • Education$961%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)92$1,830
UCB, Inc.21$544
SK Life Science, Inc.18$438
Biogen22$398
Lundbeck LLC16$381
MDD US Operations, LLC5$311
Lilly USA, LLC16$306
Alnylam Pharmaceuticals Inc.12$286
Teva Pharmaceuticals USA, Inc.12$247
Acorda Therapeutics, Inc12$232
Neurelis, Inc.12$228
Pfizer10$212
Neurocrine Biosciences, Inc.8$198
Scilex Pharmaceuticals Inc.9$194
Amgen9$183
Kyowa Kirin, Inc.9$167
Biohaven Pharmaceutical Holding Company Ltd.9$160
Upsher-smith Laboratories LLC8$150
Biohaven Pharmaceuticals, Inc.7$149
Otsuka America Pharmaceutical, Inc.6$133
Azurity Pharmaceuticals, Inc.6$125
Acadia Pharmaceuticals Inc7$124
Argenx US, Inc.5$118
Amneal Pharmaceuticals LLC5$101
Novartis6$95
Catalyst Pharmaceuticals, Inc.4$87
Jazz Pharmaceuticals Inc.4$80
Genentech USA, Inc.6$78
Avanir Pharmaceuticals, Inc.4$74
Arbor Pharmaceuticals, Inc.4$73
CSL Behring3$73
Bristol Myers Squibb3$72
AstraZeneca4$67
Sunovion Pharmaceuticals Inc.5$64
Eisai Inc.3$61
Takeda Pharmaceuticals U.S.A., Inc.2$59
Harmony Biosciences LLC3$56
ANI Pharmaceuticals, Inc.2$43
Sanofi-aventis U.S. LLC2$42
Johnson & Johnson2$42
Idorsia Pharmaceuticals US Inc2$41
Sumitomo Pharma America, Inc.2$40
Axsome Therapeutics, Inc.2$39
Greenwich Biosciences, Inc.2$36
Impel Pharmaceuticals Inc.2$36
Almatica Pharma LLC2$29
Sanofi1$26
Supernus Pharmaceuticals, Inc.1$24
Aquestive Therapeutics, Inc.1$23
Akcea Therapeutics, Inc.1$21
Collegium Pharmaceutical, Inc.1$21
GRT US Holding, Inc.1$20
Vanda Pharmaceuticals Inc.1$20
Merz Pharmaceuticals, LLC1$20
Corium, LLC1$18
Xeris Pharmaceuticals, Inc.1$17
Currax Pharmaceuticals LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,724 in reported general payments places this provider in the 90th percentile of 950 medical providers in Georgia.

See all medical providers in Georgia

Medicare billing

Part B allowed, 2024
$64,048
Medicare patients
65
Services billed
6,075

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab15$144,322
UbrelvyUbrogepant87$128,735
AustedoDeutetrabenazine16$121,010
Nurtec OdtRimegepant Sulfate61$113,646
QuliptaAtogepant44$50,631
Emgality PenGalcanezumab-Gnlm48$36,370
Ajovy AutoinjectorFremanezumab-Vfrm23$28,649
Aimovig AutoinjectorErenumab-Aooe39$28,618
NuedextaDextromethorphan Hbr/Quinidine15$23,446
NayzilamMidazolam14$23,003
XcopriCenobamate17$21,959
RytaryCarbidopa/Levodopa19$18,510
ReyvowLasmiditan Succinate13$15,427
NamzaricMemantine Hcl/Donepezil Hcl13$14,336
HorizantGabapentin Enacarbil15$10,424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Namzaric$1,830$193,702144 claims
Teva Pharmaceuticals USA, Inc.Austedo$247$121,01016 claims
PfizerNurtec Odt$212$113,64661 claims
Avanir Pharmaceuticals, Inc.Nuedexta$74$23,44615 claims
UCB, Inc.Nayzilam$544$23,00314 claims
SK Life Science, Inc.Xcopri$438$21,95917 claims
Amneal Pharmaceuticals LLCRytary$101$18,51019 claims
Lilly USA, LLCReyvow$306$15,42713 claims
Arbor Pharmaceuticals, Inc.Horizant$73$10,42415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 950 medical providers in Georgia.

Other medical in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →